Who are Treatment (Viibryd)'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treatment-viibryd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Treatment (Viibryd) — Competitive Intelligence Brief

Treatment (Viibryd) (Treatment (Viibryd)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity. Area: Psychiatry/Mental Health.

marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity Serotonin transporter (SERT); 5-HT1A receptor (partial agonist) Psychiatry/Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Treatment (Viibryd) (Treatment (Viibryd)) — Southern California Institute for Research and Education. Viibryd is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases serotonin and norepinephrine levels in the brain to treat depression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Treatment (Viibryd) TARGET	Treatment (Viibryd)	Southern California Institute for Research and Education	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity	Serotonin transporter (SERT); 5-HT1A receptor (partial agonist)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity class)

Southern California Institute for Research and Education · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Treatment (Viibryd) — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-viibryd. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab